Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines

Ma,Junfen; Guo,Xiaobing; Zhang,Shijie; Liu,Hongchun; Lu,Jing; Dong,Ziming; Liu,Kangdong; Ming,Liang

doi:10.3892/mmr.2015.3268

Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines

Authors:
- Junfen Ma
- Xiaobing Guo
- Shijie Zhang
- Hongchun Liu
- Jing Lu
- Ziming Dong
- Kangdong Liu
- Liang Ming
View Affiliations

Affiliations: Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
Published online on: January 28, 2015 https://doi.org/10.3892/mmr.2015.3268
Pages: 4525-4531

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histone deacetylase (HDAC)‑mediated epigenetic modification plays crucial roles in numerous biological processes, including cell cycle regulation, cell proliferation and apoptosis. HDAC inhibitors demonstrate antitumor effects in various cancers, including glioblastoma and breast cancer. HDAC inhibitors are therefore promising antitumor drugs for these tumors. The tumorigenesis and development of esophageal squamous cell carcinoma (ESCC) involve genetic and epigenetic mechanisms. However, the effects of the HDAC inhibitor on ESCC are not fully investigated. In the present study, ESCC cells were treated with trichostatin A (TSA) and its antitumor effects and related mechanisms were investigated. The results indicated that TSA suppressed the proliferation of ESCCs and caused G1 phase arrest by inducing the expression of p21 and p27. TSA also induced cell apoptosis by enhancing the expression of pro‑apoptotic protein Bax and decreasing the expression of anti‑apoptotic protein Bcl‑2. Furthermore, TSA inhibited the expression of phosphatidylinositol‑3‑kinase (PI3K) and reduced the phosphorylation of Akt and extracellular signal‑regulated kinase (ERK)1/2 in EC9706 and EC1 cell lines. High levels of acetylated histone H4 were detected in TSA‑treated ESCC cell lines. Overall, these results indicate that TSA suppresses ESCC cell growth by inhibiting the activation of the PI3K/Akt and ERK1/2 pathways. TSA also promotes cell apoptosis through epigenetic regulation of the expression of apoptosis‑related protein.

View Figures

View References

1	Zhu H, Huo X, Chen L, Wang H and Yu H: Clinical experience with radio-, chemo- and hyperthermotherapy combined trimodality on locally advanced esophageal cancer. Mol Clin Oncol. 1:1009–1012. 2013.
2	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
3	Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
4	Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
5	Reichert N, Choukrallah MA and Matthias P: Multiple roles of class I HDACs in proliferation, differentiation and development. Cell Mol Life Sci. 69:2173–2187. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ellis L, Atadja PW and Johnstone RW: Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 8:1409–1420. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ellis L and Pili R: Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel). 3:2411–2469. 2010. View Article : Google Scholar
8	Abbas A and Gupta S: The role of histone deacetylases in prostate cancer. Epigenetics. 3:300–309. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bonfils C, Walkinshaw DR, Besterman JM, Yang XJ and Li Z: Pharmacological inhibition of histone deacetylases for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. Expert Opin Drug Discov. 3:1041–1065. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ropero S and Esteller M: The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25. 2007. View Article : Google Scholar : PubMed/NCBI
11	Cress WD and Seto E: Histone deacetylases, transcriptional control and cancer. J Cell Physiol. 184:1–16. 2000. View Article : Google Scholar : PubMed/NCBI
12	Meng F, Sun G, Zhong M, Yu Y and Brewer MA: Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3. Int J Oncol. 43:495–502. 2013.PubMed/NCBI
13	Ueki N, Lee S, Sampson NS and Hayman MJ: Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease. Nat Commun. 4:27352013. View Article : Google Scholar : PubMed/NCBI
14	Wilson PM, Labonte MJ, Martin SC, et al: Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 31:845–857. 2013. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Xiao W, Chen W, Luo L, Ye S and Liu Y: The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis. 4:e8842013. View Article : Google Scholar : PubMed/NCBI
16	Stein C, Riedl S, Rüthnick D, Nötzold RR and Bauer UM: The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes. Nucleic Acids Res. 40:9522–9533. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cai Y, Cui W, Chen W, et al: The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms. Cancer Cell Int. 13:572013. View Article : Google Scholar : PubMed/NCBI
18	Spiegel S, Milstien S and Grant S: Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 31:537–551. 2012.
19	Mutze K, Langer R, Becker K, et al: Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol. 17:3336–3343. 2010. View Article : Google Scholar : PubMed/NCBI
20	Jurkin J, Zupkovitz G, Lagger S, et al: Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle. 10:406–412. 2011. View Article : Google Scholar : PubMed/NCBI
21	Hoshino I and Matsubara H: Recent advances in histone deacetylase targeted cancer therapy. Surg Today. 40:809–815. 2010. View Article : Google Scholar : PubMed/NCBI
22	Noureen N, Rashid H and Kalsoom S: Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol. 66:625–633. 2010. View Article : Google Scholar : PubMed/NCBI
23	Marson CM: Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem. 9:661–692. 2009. View Article : Google Scholar : PubMed/NCBI
24	Rezaei PF, Fouladdel S, Hassani S, et al: Induction of apoptosis and cell cycle arrest by pericarp polyphenol-rich extract of Baneh in human colon carcinoma HT29 cells. Food Chem Toxicol. 50:1054–1059. 2012. View Article : Google Scholar
25	Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH and Ronen SM: HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One. 8:e626102013. View Article : Google Scholar : PubMed/NCBI
26	Watson JA, McKenna DJ, Maxwell P, et al: Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profiles. J Cell Mol Med. 14:1668–1682. 2010. View Article : Google Scholar
27	Gerard C and Goldbeter A: From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle. Front Physiol. 3:4132012. View Article : Google Scholar : PubMed/NCBI
28	Yagi Y, Fushida S, Harada S, et al: Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res. 29:1492010. View Article : Google Scholar : PubMed/NCBI
29	Wang C, Fu M, Mani S, Wadler S, Senderowicz AM and Pestell RG: Histone acetylation and the cell-cycle in cancer. Front Biosci. 6:D610–D629. 2001. View Article : Google Scholar : PubMed/NCBI
30	Aguero MF, Facchinetti MM, Sheleg Z and Senderowicz AM: Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 65:3364–3373. 2005.PubMed/NCBI
31	Queiroz AB, Focchi G, Dobo C, Gomes TS, Ribeiro DA and Oshima CT: Expression of p27, p21 (WAF/Cip1) and p16 (INK4a) in normal oral epithelium, oral squamous papilloma and oral squamous cell carcinoma. Anticancer Res. 30:2799–2803. 2010.PubMed/NCBI
32	Tula-Sanchez AA, Havas AP, Alonge PJ, et al: A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther. 14:949–961. 2013. View Article : Google Scholar : PubMed/NCBI
33	You BR and Park WH: Trichostatin A induces apoptotic cell death of HeLa cells in a Bcl-2 and oxidative stress-dependent manner. Int J Oncol. 42:359–366. 2013.
34	Hacker S, Karl S, Mader I, et al: Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation. Oncogene. 30:2275–2281. 2011. View Article : Google Scholar : PubMed/NCBI
35	Zhang J, Roberts TM and Shivdasani RA: Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 141:50–61. 2011. View Article : Google Scholar : PubMed/NCBI
36	Chen CS, Weng SC, Tseng PH, Lin HP and Chen CS: Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem. 280:38879–38887. 2005. View Article : Google Scholar : PubMed/NCBI
37	Liu B and Kuang A: Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 29:1221–1225. 2012.In Chinese.